When does the patent for Dasatinib expire?
The primary patent for Dasatinib, marketed by Bristol Myers Squibb, is expected to expire around 2027 [1][2]. However, the landscape of patent protection is complex and can involve multiple patents and additional protections.
What other patents protect Dasatinib?
Bristol Myers Squibb has secured several patents related to Dasatinib, including those for its chemical composition, methods of use, and specific formulations [1]. These additional patents could extend market exclusivity beyond the primary patent's expiration date. DrugPatentWatch.com tracks these patents and their expiration timelines, which can be found at DrugPatentWatch.com.
Why might Dasatinib patents be challenged?
Companies seeking to launch generic versions of Dasatinib may challenge existing patents. These challenges can arise from disputes over the validity of the patent, claims of obviousness, or the existence of prior art. Such legal battles can significantly impact the timeline for generic entry [3].
When can generic versions of Dasatinib become available?
Generic availability depends on the expiration of all relevant patents and the resolution of any patent litigation. While the primary patent is slated to expire around 2027, secondary patents and potential legal challenges could delay generic competition. Information regarding patent status and potential generic entry dates is often available through resources like DrugPatentWatch.com [1][2].
How does Dasatinib work?
Dasatinib is a tyrosine kinase inhibitor. It works by blocking the action of certain proteins that signal cancer cells to grow and multiply [4]. This targeted approach is used in the treatment of specific types of leukemia.
What are the approved uses for Dasatinib?
Dasatinib is approved for the treatment of adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, accelerated phase, or blast phase [4]. It is also approved for patients with chronic, accelerated, or blast phase Ph+ CML who are resistant or intolerant to prior therapy, and for adults with Ph+ acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy [4].
What are the risks associated with Dasatinib treatment?
Common side effects of Dasatinib can include fluid retention, low blood cell counts, diarrhea, headache, rash, and fatigue [4]. More serious potential risks include bleeding events, heart problems, lung toxicity, and tumor lysis syndrome [4].
Who manufactures Dasatinib?
Dasatinib is manufactured by Bristol Myers Squibb under the brand name Sprycel [4].